Article
Biochemistry & Molecular Biology
Hyo Jin Choi, Mun Han, Byeongjin Jung, Yu-Ri Hong, Seulgi Shin, Sungsu Lim, Eun-Hee Lee, Yun Kyung Kim, Juyoung Park
Summary: This study demonstrates the potential of MRgFUS as a delivery system to enhance the efficacy of therapeutic drugs for Alzheimer's disease. The use of MRgFUS significantly improved the brain accumulation of methylene blue and reduced the deposition of amyloid-beta plaques.
Article
Biophysics
Xueao Wang, Yani Liu, Xueting Wang, Xiaolian Ye, Wei Cheng, Guiquan Chen, Hai-Liang Zhu, Jing Zhao, Yong Qian
Summary: This study developed a novel class of fluorescent dyes with two-photon excitation and near-infrared emission, which enables real-time imaging of amyloid plaques in the brain.
BIOSENSORS & BIOELECTRONICS
(2023)
Review
Biochemistry & Molecular Biology
Adolfo Lopez-Ornelas, Adriana Jimenez, Gilberto Perez-Sanchez, Citlali Ekaterina Rodriguez-Perez, Alejandro Corzo-Cruz, Ivan Velasco, Enrique Estudillo
Summary: Alzheimer's disease is a common neurodegenerative disorder with increasing prevalence. Understanding its pathophysiology is crucial for developing effective treatment. Despite recent efforts in drug development, the neuronal damage caused by Amyloid beta peptide and Tau protein abnormalities remains a challenge. Peripheral inflammation is closely associated with the onset and progression of AD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Katarzyna Potyrak, Benita Wiatrak, Edward Krzyzak, L. Lukasz Szczukowski, Piotr Swiatek, Adam Szelag
Summary: Alzheimer's disease remains a serious disorder with no effective therapy. However, certain compounds show potential for beneficial effects on damaged neuronal cells and are capable of crossing the blood-brain barrier.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Neurosciences
Yang An, Yue Qi, Ying Li, Zhao Li, Caiyu Yang, Dong Jia
Summary: Activation of sigma-1 receptors by PRE-084 attenuated BBB disruption and reduced A beta levels in AD mice, leading to improved learning and memory deficits. Upregulation of VEGF and LRP-1 levels by sigma-1 receptors may play a role in this process.
NEUROSCIENCE LETTERS
(2022)
Article
Clinical Neurology
Rosemary J. Jackson, Jonah C. Meltzer, Huong Nguyen, Caitlin Commins, Rachel E. Bennett, Eloise Hudry, Bradley T. Hyman
Summary: The study demonstrates that APOE4 leads to a leaky blood-brain barrier, and astrocyte-produced APOE4, through its interaction with blood vessels, is a crucial regulator of blood-brain barrier integrity.
Article
Biochemistry & Molecular Biology
Anett Hudak, Annamaria Letoha, Csaba Vizler, Tamas Letoha
Summary: Early diagnosis of Alzheimer's disease is crucial for preserving patients' health, and the expression of SDC3 in experimental models suggests it could be used as a biomarker for detecting neurodegeneration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Liqiang Hu, Yiran Tao, Yanjiao Jiang, Feng Qin
Summary: Alzheimer's disease is the most common cause of memory disruption in elderly individuals, and the lack of effective therapy is due to low drug potency and challenges in drug delivery. Recent advances in nanomedicine have shown promising developments in Alzheimer's disease treatment, using various nano-carriers to develop successful strategies. This review comprehensively summarizes the efficacy of different nanomedicine in pre-clinical studies and provides insights and future research directions. It can guide the design and evaluation of nanomedicine in Alzheimer's disease treatment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Pharmacology & Pharmacy
Geetika Nehra, Bjoern Bauer, Anika M. S. Hartz
Summary: This review summarizes the extent and clinical relevance of barrier leakage in Alzheimer's disease (AD). By examining animal models, clinical and postmortem studies, signaling mechanisms, and potential therapeutic strategies, the review provides insights into the relationship between barrier leakage and neurodegeneration, cognitive decline, and the development of novel therapeutic targets for AD.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Biochemistry & Molecular Biology
Chanchal Sharma, Hanwoong Woo, Sang Ryong Kim
Summary: The blood-brain barrier is essential in maintaining the brain microenvironment, and disruptions to it can be linked to cognitive impairments such as Alzheimer's disease. By studying the mechanisms of BBB breakdown, we can better understand neurodegenerative diseases. Additionally, BBB disruption can serve as a biomarker for diagnosing cognitive impairments.
Article
Clinical Neurology
Andrew G. Murchison
Summary: This article posits that amyloid deposition and increased permeability of the blood-brain barrier are early independent events in Alzheimer's disease pathophysiology, contributing to a distinct microglial activation phenotype. Downstream effects such as synapse phagocytosis and persistent glutamate signally through NMDA receptors lead to neurodegeneration and tau pathology. This hypothesis aims to shed light on unexplained temporal and spatial features of AD by drawing from multiple lines of evidence.
ALZHEIMERS & DEMENTIA
(2022)
Review
Cell Biology
Ming Zhao, Xue-Fan Jiang, Hui-Qin Zhang, Jia-Hui Sun, Hui Pei, Li-Na Ma, Yu Cao, Hao Li
Summary: Alzheimer's disease is an irreversible neurodegenerative disorder with no satisfying curative therapies currently available. Dysfunction of the blood-brain barrier contributes to the onset and progression of AD, yet the pathogenesis caused by BBB injury remains unclear. Glial cells play a crucial role in maintaining the integrity of BBB and neuronal function.
AGEING RESEARCH REVIEWS
(2021)
Article
Pharmacology & Pharmacy
Sanjay Arora, Jagdish Singh
Summary: The research demonstrated a brain-targeted nanoparticle delivery system for vgf gene, showing significant transfection in the mouse brain for the treatment of Alzheimer's disease. This method utilized surface functionalization and lipid conjugation for efficient brain-targeted transfection, with promising results in vivo.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Nanoscience & Nanotechnology
Manju Sharma, Virendra Tiwari, Swati Chaturvedi, Muhammad Wahajuddin, Shubha Shukla, Jiban Jyoti Panda
Summary: This study developed self-fluorescent nanoparticles as a therapeutic system for Alzheimer's disease (AD), showing the ability to inhibit and disrupt the amyloid fibrils associated with AD. These nanoparticles were nontoxic to neural cells and protected neurons from cytotoxicity. Animal model experiments demonstrated that the nanoparticles improved memory in AD model rats. Overall, the nanoparticles showed promising potential as nanotheranostic agents for AD therapy.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Clinical Neurology
Manon Leclerc, Philippe Bourassa, Cyntia Tremblay, Vicky Caron, Camille Sugere, Vincent Emond, David A. Bennett, Frederic Calon
Summary: This study reveals that impairment of insulin receptors at the blood-brain barrier contributes to brain insulin resistance in Alzheimer's disease, in association with beta-amyloid pathology, based on experiments with human brain samples and animal models.